Study: No benefit from intermittent therapy in prostate cancer

04/4/2013 | HealthDay News

Patients with metastatic prostate cancer who received intermittent androgen deprivation therapy had a 10% greater risk of mortality than those who got continuous hormone treatment, according to a study published in the New England Journal of Medicine. Researchers tracked more than 1,500 patients and found average survival rates of 5.8 years for the continuous therapy group and 5.1 years for the intermittent treatment group. Men who received intermittent treatment initially reported better quality of life and mental health, but those gains were lost by the end of the study.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA